# Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia

> **NCT02612545** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 216 (actual)

## Conditions studied

- Acute Falciparum Malaria

## Interventions

- **DRUG:** Dihydroartemisinin-piperaquine (DHA-PPQ)
- **DRUG:** Mefloquine (MQ)

## Key facts

- **NCT ID:** NCT02612545
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-20
- **Primary completion:** 2018-10-12
- **Final completion:** 2019-10-08
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2019-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612545, "Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02612545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*